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auidelines on Valvular Heart Disease
merican College of Cardiology/American Heart Asso-
iation (1).
Comment: A total of 124 pages and 1,066 references. Of
he 324 recommendations, 1 (0.3%) and 242 (74.7%) are on
he basis of the Level of Evidence A and C, respectively.
evel of Evidence “C”: Consensus opinion of experts, case
tudies, standard of care.
uropean Society of Cardiology (2).
Comment: A total of 32 pages and 232 references. Of the
4 recommendations, 0 and 58 (90.6%) were on the basis of
he Level of Evidence A and C, respectively. Level of
vidence C: Consensus of opinion of the experts, and/or
mall studies, retrospective studies, registries.
ortic Stenosis (AS)
arly identification of aortic valve (AV) disease. Molecu-
ar imaging with the use of in vivo panel of near-infrared
uorescence imaging agents in AV of hypercholesterolemic
polipoprotein E-deficient mice (3) demonstrated that AV
ontained macrophages, that the macrophages were thicker
han in wild-type mice, and that early dysfunction de-
ected with magnetic resonance imaging in vivo and fluo-
escence imaging enabled researchers to detect uptake of
acrophage-targeted magnetofluorescent nanoparticles.
alvular macrophages showed proteolytic activity. Endo-
helial activation and active osteogenesis were observed in
alve commissures and inflamed valves, respectively (Fig. 1).
he aortic wall contained advanced calcification.
alcific AS in old hypercholesterolemic mice. Twenty-
our genetic knockout mice that lack the gene for the
ow-density lipoprotein (LDL) receptor and express only
he receptor for the human apolipoprotein B-100 (LDL/
rom the Griffith Center, Division of Cardiovascular Medicine, Department of
edicine, LACUSC Medical Center, Keck School of Medicine at University of
outhern California, Los Angeles, California. Dr. Rahimtoola has received Honoraria
or educational lectures from American College of Cardiology Foundation; American
ollege of Physicians; University of California Los Angeles; University of California
rvine; Cornell University; Creighton University; Thomas Jefferson University;
edars-Sinai Medical Center; Harvard Medical School; University of Wisconsin;
niversity of Hawaii; Cardiologists Association of Hong Kong, China; ATS; St. Jude
edical; Carbomedics; Merck; Pfizer; Edwards Life Sciences. This review covers the
eriod from July 2006 to June 2007.a
Manuscript received September 19, 2007; revised manuscript received November
1, 2007, accepted November 28, 2007.poB100/100) were fed normal chow until age 20.1 months.
wenty-one age-matched C57 B1/6 mice served as con-
rols. Aortic stenosis with 75% reduction in valve area
ccurred in 8 of 24 mice and in no control mice (p  0.01)
4). Hypercholesterolemic mice were prone to develop AV
alcification and oxidative stress (Fig. 2). At cardiac cathe-
erization, the mean AV gradient was 57  6 mm Hg, left
entricular (LV) mass was increased by 67%, and left
entricular ejection fraction (LVEF) was decreased by 30%.
ow fetuin-A correlates with calcification. Fetuin-A is a
erum-based inhibitor of calcification. In 970 ambulatory
ersons with coronary heart disease and without severe
idney disease, 20% had mitral annular calcification and 8%
ad AS (5). There was an inverse relationship between
etuin-A and mitral annular calcification as well as AS.
Comment: An accompanying editorial comment presents
review of fetuin-A (6).
ransforming growth (TGF)-1 and AV calcification.
he use of TGF-1 caused sheep AV interstitial cells to
alcify as the result of an early maximal increase in alkaline
hosphatase activity with associated apoptotic events and
ncreased matrix metalloproteinase 9. A similar gene expres-
ion pattern changes was observed in calcific AS valves
btained at surgery (7).
Comment: The use of TGF-1 is known to stimulate
ollagen development by fibroblasts, which could have
istorted the valves irrespective of the calcium.
ower serum calcium levels and calcific AS. A total of
28 excised valves showed a trend toward greater levels of
alve calcification (r  0.15, p  0.026) (8), which
ppeared only in men whose valves contained more hy-
roxyapatite than in women (26  9% vs. 22  9% of valve
ass; p  0.001).
Comment: This study indicates the importance of calcium
ndependent of calcium metabolism or renal function.
he genetic background of AS and coronary artery
isease (CAD) are different. A total of 538 patients with
evere AS and 536 controls (no heart disease age65 years)
ere studied (9). Apolipoprotein E (ApoE) is an essential
tructural component of cholesterol and is expressed in
iseased valves. There were no significant differences in
poE e2, e3, and e4 between patients with AS and controls
nd in AS between those with and without CAD. The
uthors concluded that “ApoEe4 is not associated with AS
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February 19, 2008:760–70 Year in Valvular Heart Diseaseeflecting the different genetic background of AS and
AD.”
se of rosuvastatin slowed the progression of moderate
S in patients with marked increases of LDL choles-
erol. An open-label, prospective study (10) of 121 patients
as undertaken, 61 of whom were treated with rosuvastatin
or 18 months and 60 of whom who were not. Patients had
oderate AS, and the mean gradient in the 2 groups was
5.3  13.4 mm Hg and 36.1  13.4 mm Hg. At baseline,
any differences existed between the 2 groups, including
DL, which in the treated group was 158.2  31.7 mg/dl
nd in the nontreated group was 116.5  20.9 mg/dl. Two
rimary end points were progression of AS and improve-
ent in LDL cholesterol.
Echocardiographic/Doppler data were obtained by 2
Figure 1 Valvular Myofibroblasts Exhibit Osteoblastic
Activity in the Early Stage of Aortic Valve Stenosis
(A) Multicolor fluorescence imaging simultaneously visualized 2 different bio-
logical processes: osteogenesis (red) and inflammation (green). (B) Correla-
tive histopathologic analysis with multichannel near infrared microscopy-
detected osteoblastic activity (red on merged image) and inflammation (green
on merged image). Near infrared osteogenic signal localized alkaline phospha-
tase activity elaborated by alpha-smooth muscle actin, osteocalcin and
osteopontin, osteogenic transcription factors Runx2/Cbfa 1, and osterix and
cleaved Notch 1, which suggests active processes of ongoing mineralization.
Staining with von Kossa and Alizarin red showed no evidence of microscopic
mineralization in the leaflets, but cross sections through the aortic arch
showed prominent calcification. Magnification 400. From Aikawa et al. (3).nvestigators who were blinded to the treatments.There was a significant reduction of LDL cholesterol
nly in the treated group, from 159.7  33.4% to 93.3 
1.1% (p  0.001). Aortic valve area (AVA) in the treated
roup changed from 1.22  0.40 to 1.16  0.42 (p  0.01)
nd in the untreated group changed from 1.24  0.35 to
.11  0.35 (p  0.001). In the treated group the
orrelation of change in LDL cholesterol to change in mean
radient was very weak: r  0.224, p  0.027.
Comment: This was a nonrandomized, open-label, obser-
ational, very short-term study that nevertheless is of
nterest. The areas of concern include: 1) the large difference
f LDL cholesterol at baseline between the 2 groups and 2)
small change in AVA in the treated group (mean differ-
nce 0.06 cm2). The intraobserver and interobserver coeffi-
ients of reproducibility of AVA were 0.22 cm2 and 0.18
m2, respectively.
ortic Regurgitation (AR)
Improved” outcome after aortic valve replacement
AVR) for chronic AR with severe LV dysfunction. A
otal of 724 patients had AVR from January 1972 to January
999. With the use of propensity matching, saturating mod-
ling, greedy matching strategy, estimating shaping parame-
ers, and bootstrap bagging, a propensity score for each patient
was then found,” which was then forced into the model to
further adjust for known differences between patients.”
Of 88 patients with severe left ventricular dysfunction
LVD) (i.e., LVEF  0.30) 53 had AVR before January 1,
985, with 17% operative mortality and 35 patients who had
VR after that date with 0% operative mortality (11). Of
he entire group, those with proximity-matched survival in
hose with “nonsevere” LVD (n  71; ? operative survivors)
ersus those with severe LVD (n 62; ? operative survivors)
as 62% versus 46%, respectively, at 10 years (numbers at
isk 27 and 17) and 12% versus 5%, respectively, at 25 years
numbers at risk 2 and 1).
Figure 2 Valve Calcification in the Genetic Knockout Mice
von Kossa staining of aortic valve tissue. Mineralization of tissue appears as
discrete dark foci (right). L  leaflet; LA  leaflet attachment. Bar left  0.3
mm. From Weiss et al. (4).
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Year in Valvular Heart Disease February 19, 2008:760–70In propensity-matched patients who underwent surgery
n 1985 and beyond, 10-year survival in 35 patients with
evere LVD was 51% and in 37 patients with nonsevere
VD was 55% (p 0.9). The authors’ main conclusion was
hat “Neutralizing risk of severe LVD has improved early
nd late survival such that aortic valve surgery for chronic
R and cardiomyopathy is no longer a high-risk proce-
ure. . ..”
Comment: Can multiple, complex biostatistical analyses
ccurately correct the problems of a study? The authors’
ain conclusion is based on a comparison of 35 and 37
atients. Some of the important missing information is as
ollows: 1) In each of the 2 groups, the number of patients
ho had coronary arteriography, the percent of them who
ad significantly obstructive CAD, and the percent of these
ho had coronary artery bypass graft (CABG). The survival
ifference at 25 years between patients with nonsevere LVD
nd severe LVD is largely caused by a high operative
ortality in the latter group. Can the high (17%) operative
ortality before 1985 be explained by CAD that was not
ypassed? 2) In the group of severe LVD, the mean  SD
nd range of LVEF and the number of patients with LVEF
0.25 (see below). 3) No data on changes in LV size and
unction and patients’ functional class were supplied. An
arlier study of 17 consecutive patients who underwent
urgery from 1973 to 1977 had AVR for severe AR with
VEF (0.25 to 0.49) plus CABG in 3 and ascending aortic
neurysm correction in 2 (12). The operative mortality was
, and at follow-up 14.5  3 months later, there were
tatistically significant decreases in LV end-diastolic pres-
ure, LV end-diastolic and LV end-systolic volumes, and
V mass. Left ventricular volumes and LVEF normalized
n 20% and 40% of patients, respectively, who were restud-
ed, and almost all of the patients were in New York Heart
ssociation (NYHA) functional classes I and II.
icuspid Aortic Valve (BAV)
ndothelial nitric oxide synthase (eNOS) protein expres-
ion in BAV. Endothelial nitric oxide synthase protein
xpression of aortic endothelial cells was lower in BAV than
n tricuspid aortic valve (p  0.017) (13). In patients with
AV, there was significant correlation between eNOS and
aximum aortic diameter (r  0.530, p  0.029) and
inotubular diameter (r  0.520, p  0.033), which were
ot observed with tricuspid aortic valve.
Comment: Additional studies are needed to determine the
ignificance of this finding in an increasingly important
linical condition.
educed aortic elasticity in nonstenotic BAV. Patients
ith BAV showed reduced aortic elasticity, aortic root
istensibility, and aortic root dilation compared with control
ubjects when studied with magnetic resonance imaging
14). Reduced aortic wall elasticity correlated with severity
f AR and LV mass. sitral Stenosis
ultislice computed tomography (MSCT). Mitral valve
rea as determined with MSCT in 29 patients (1.51  0.47
m2, range 0.85 to 2.4 cm2) correlated with mitral valve area
MVA) that was determined with echocardiography (1.44
0.53 cm2, range 0.7 to 2.3 cm2, r  0.88, p  0.0001).
land-Altman analysis showed the range of difference
etween the 2 methods was 0.20  0.17 cm2 (15).
itral Regurgitation (MR)
enetic cause of myxomatous valve disease. X-linked
yxomatous valvular dystrophy is a rare form of inherited
onsyndromic valvular dystrophy that was previously
apped to chromosome Xq28. This study identified a
637Q mutation in the filamin A gene in all affected
embers (16). Clinically, patients present with mitral valve
rolapse, MR, and/or AR. Among carriers of FLN muta-
ion, the penetrance of the disease was complete in men and
as incomplete in women. Female carriers could be mildly
ffected, and the severity of the disease was highly variable
mong mutation carriers.
Comment: Additional studies are needed to determine the
ignificance of this finding in an increasingly important
linical condition.
andomized trial of rings with mitral valve repair
MVrep). A total of 363 patients underwent MVrep by
arpentier technique plus Carpentier rigid ring (n  186)
r Duran flexible ring (n  170) (17). Operative mortality
as 1.1%. Follow-up was for 3 to 126 months (mean 46.6
onths). There was no difference in survival, LV systolic
unction, and freedom from significant MR between the
groups.
Comment: Previous studies have documented the benefi-
ial effects of the addition of a ring to mitral valve repair.
his is a useful randomized trial that determined that the
ype of ring does not influence severity of subsequent MR.
uro Heart Survey: symptomatic patients with severe
R but denied surgery. A total of 396 hospitalized
atients were studied, with an age 66  13 years, of whom
0% were 80 years and 35% were age 70 to 80 years.
itral valve prolapse was present in 53%, and 40% had 1
omorbidity. Coronary arteriography was performed in
8%, and CAD was present in 44% of these patients (18).
he decision to operate was taken in 203 (67%). In
ultivariate analysis, the reasons not to operate were lower
VEF, nonischemic etiology, older age, higher Charlson
omorbidity index, and grade 3 MR. The 1-year survival
as 96 1.4% in those recommended for surgery (only 67%
f whom had surgery during the survey period) and in those
ho did not undergo surgery (“denied surgery”) was 89.5 
.3% (p  0.02).
Comment: The Euro Heart Survey for valvular heart
isease (VHD) is an important study; the concern does not
elate to findings but the conclusion “denied surgery.” It
eems accusatory. Determining the precise reason(s) for not
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February 19, 2008:760–70 Year in Valvular Heart Diseaseecommending surgery is difficult from a survey if specific
uestions are not included and if the actual medical record
s not reviewed. The reasons usually are multifactorial;
atients in their 70s and 80s do refuse surgery. Patients were
ospitalized and must have had complications of MR or had
ther problems; their symptoms may not have been due to
R. In patients in whom surgery was not recommended,
he incidence of comorbid conditions was greater, for example,
f heart failure (HF), previous myocardial infarction, very low
VEF, diabetes, and chronic obstructive pulmonary disease.
here is no trial showing improved survival and outcomes
ith surgery in such a group of patients. The better term
ight be “surgery was not recommended.”
ospital procedural volume on care process for MR
urgery. The Society of Thoracic Surgeons Database has
nformation on 13,614 patients who underwent MV surgery
etween 2000 and 2003 (19). Hospital annual MV volume
or the lowest-volume quartile (LVQ) was 22 cases per year,
nd the highest-volume (HVQ) was 394. The risk-adjusted
atio for hospital mortality in the HVQ compared with the
VQ was 0.48 (95% confidence interval 0.28 to 0.82). The
ate of MVrep in the LVQ was 47.7% and in the HVQ was
7.4% (p  0.0001). The association between volume and
ortality when adjusted for operation type was attenuated
rom an odds ratio of 0.48 to 0.59 (95% confidence interval
.35 to 1.01, p  0.05).
Comment: There is a need for considerable caution to
xtrapolation of these findings to all low-volume centers
ecause: 1) the odds ratio narrowed when adjustments were
ade for operation type and 2) there might be a chance that
ll risk factors may not have been accounted for, for
xample, indications for surgery. Surgeons in hospitals with
VQ may tend to operate on minimally symptomatic or
symptomatic patients; it is possible that the clinical con-
ition of the patients were also different.
urgery for MR in the elderly. Patients age 75 years (n
284), operated for MR in 1980 to 1983, 1984 to 1987,
988 to 1991, and 1992 to 1995 were compared with
ounger patients (65 to 74 years, n  504 and 65 years, n
556). Preoperative risk characteristics were more severe in
lderly patients (all p  0.002). In the 4 time periods,
Vrep was performed in 30%, 46%, 81%, and 84%, respec-
ively (20). The observed 5-year survival in the 3 groups
75, 65 to 74, and65 years) was 57 3%, 73 2%, and
5  2% (p  0.001), the ratio of observed (after excluding
perative mortality) to expected survival in these 3 groups
as 83%, 85%, and 88%, respectively. Temporal trends
howed that risk of operative mortality, although greater in
lderly patients (p  0.001), declined markedly for all 3
atient groups from 27% to 5% (p  0.001), 21% to 4% (p
0.001), and 7% to 2% (p  0.06), respectively.
Comment: These results demonstrate a remarkable ad-
ance of surgery. Areas of concern include: 1) The number
f patients in each of the NYHA functional classes I and II
re not described, which in those age 75 years totaled
0%. 2) In the latest era (1992 to 1995) MVrep waserformed in 84%. Thus, 16% had MVR, and one should be
autious about extrapolating these data to recommending
urgery to patients in NYHA functional class II and
articularly to those in class I. 3) The percent of patients
een at their institution during each of the 4 time periods
ith similar characteristics as in this study but who did not
ave surgery would be important to know. 4) The entry of
atients ended in 1995, and only the 5-year survivals are
eported 11 years later in 2006. The 10-year survival data are
ot reported in the text but only in Figure 1A, after
xcluding operative mortality, appears to be about 20%,
0%, and 70%. 5) Finally, it would have been important to
now whether the “recent” benefit was maintained from
996 to 2000 and 2001 to 2004.
ricuspid Regurgitation (TR)
hanges in tricuspid valve annular (TVA) shape with
unctional TR. Tricuspid valve annulus was studied with
eal-time 3-dimensional echocardiography in 35 patients
ith functional TR and 40 with normal tricuspid valve
unction. Annular area and mediolateral in addition to
nteroposterior and high (superior)-low (inferior) distances
ere calculated (Fig. 3) (21). The normal TVA has a
imodal pattern (high-low distance  7.23  1.05 mm).
ith  moderate TR, TVA become dilated (TR vs.
eferent, 17.4  4.75 cm2 vs. 9.83  2.18 cm2, p 
.0001), more planar with decreased high-low distance
4.14 1.05 mm), and more circular with decreased ratio of
ediolateral/anteroposterior (TR vs. referent, 1.11  0.09
s. 1.32  0.09, p  0.001).
ricuspid valve repair (TVrep) with an annuloplasty ring
mproves outcomes. Of 702 patients who underwent
Vrep, 493 had predominantly a De Vega procedure (no
ing) and 209 also had an annuloplasty (ring) (22). At 15
ears, comparison of “ring” versus “no ring” survival was 49
5% versus 36 8%, p 0.007; event-free survival was 34
Figure 3 3-Dimensional View of Tricuspid
Valve Relative to Anatomic Structures
(A) Tricuspid valve viewed from the atrium. The valve relative to anatomic
structures is displaced, demonstrating the location of high and low points.
(B) Dilation along the free wall aspect of the tricuspid valve with functional tri-
cuspid regurgitation (dashed lines). Ao  aorta; RVOT  right ventricular out-
flow tract. From Ton-Nu et al. (21).
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Year in Valvular Heart Disease February 19, 2008:760–705% versus 17  6%, p  0.01; and freedom from
ecurrent TR was 82  5% versus 39  11%, p  0.03.
ultivariate analysis showed use of an annuloplasty ring
as an independent predictor of survival and event-free
urvival.
Comment: Similar to MVrep, annuloplasty is not as
ffective as ring plus annuloplasty.
nfective Endocarditis (IE)
utcome of urgent surgery for IE. A total of 89 of 508
18%) consecutive episodes of IE needed urgent surgery;
2% of them for HF unresponsive to medication and 31%
or persistent infection despite appropriate antibiotic treat-
ent (23). Hospital mortality was 36%; multivariate anal-
sis showed that persistent infection and renal insufficiency
ere independent predictors of mortality.
ong-term survival after surgery. Of 383 consecutive
atients who underwent surgery for active IE, native valve
as involved in 266 and prosthetic heart valves (PHVs) in
17. Operative mortality was 12%, and late deaths were 23%
24). At 15 years, survival was 44  5%; for native valve IE
as 59  5%; and for PVE was 25  7% (p  0.001) (Fig.
). At 15 years, freedom from recurrent IE was 86  3%
nd from reoperation was 70 6%; both events were similar
or native valve and prosthetic valve endocarditis (PVE).
urgery improves survival. A prospective study of 203
pisodes in 193 patients showed PVE occurred in 34%. A
otal of 33% of episodes were nosocomial (25), 43% were
taphylococcus aureus, 26% streptococcal, and 17% entero-
occi. At least 1 complication occurred in 79% of the
pisodes, and 63% had surgical intervention. Six-month
ortality was 22%; 33% for staphylococci, 24% for entero-
occi, and 8% for streptococci. A total of 74% of those with
contraindication to surgery died. By multivariate logistic
egression, predictors of 6 month mortality were age (p 
.03), the causative microorganism (p  0.04), and treat-
ent group (p  0.001).
In 116 consecutive patients with staphylococcal IE, hos-
ital mortality was 26%, and 3-year survival was 57  5%
Figure 4 Long-Term Survival of Patients With Endocarditis
of Native and Prosthetic Valve After Surgery
From David et al. (24).t26). Hospital and 3-year mortality were related to compli-
ations and comorbidities; the rate of hospital mortality was
ower with early surgery (16% vs. 34%, p  0.034); 3-year
urvival was better with early surgery than with medical
herapy (77  6% vs. 39  7%, p  0.001).
A total of 364 consecutive patients had surgery for IE.
urvival at hospital discharge and 5 and 10 years for surgical
atients was 91%, 69%, and 41% and for medically treated
atients was 85%, 60%, and 31%, respectively, p  0.001
27).
A total of 69 patients on hemodialysis with IE were
dentified. Duration of dialysis was 37  32 months (28).
. aureus was the organism in 57.9%, of whom 43.5% were
ethicillin resistant. Fifteen patients had valve surgery.
ospital mortality was 49.3%. More patients who had
urgery survived than patients who did not (odds ratio 5.39,
5% confidence interval 1.3 to 17.6, p  0.018). Surgery
as the only independent factor predicting survival (p 
.023).
urgery does not improve survival in patients with
eft-sided IE. A total of 546 patients who had IE between
980 and 1998 were included (29). There were many
tatistically significant differences at baseline between the
urgical (n  129) and nonsurgical (n  417) groups. After
ultiple statistical analyses, including propensity scoring,
djustments for survivor bias by matching follow-up times,
nd valve surgery as a time-dependent covariate in different
ox models, all models were adjusted for prognostic vari-
bles “known to be predictive of 6-month mortality,” and
fter adjustment for early (operative) mortality, surgery was
ot associated with a survival benefit up to 6 months of
ollow-up (adjusted hazard ratio 0.92, 95% confidence
nterval 0.48 to 1.76), numbers of patients at-risk not given.
he authors concluded that “Given the disparity between
he results of our study and those of other observational
tudies, well-designed prospective studies are needed to
urther evaluate the role of valve surgery in endocarditis
anagement.”
Comment: Can multiple biostatistical analyses accurately
orrect the many complex study problems? A few of the
any clinical issues include the following: 1) Because
ollow-up was only 6 months, why did the recruitment of
atients end in 1998 when the study is published in 2007?
) The long delay (30 days) between onset of diagnosis and
urgery suggests there was extensive valve destruction/
isruption and extension of infection (e.g., abscess) beyond
he valve (See MVrep study below and urgent surgery study
bove). Should the patients have had surgery very much
arlier? 3) There are 12 authors but none from the Division
f Cardio-Thoracic Surgery and 2 cardiologists, one from
anada and one from Scottsdale, Arizona, but none from
ochester, Minnesota; and 4) When a prospective study is
esigned, the authors should ensure that a clinical cardiol-
gist is responsible for the care of the patient and that the
ecision for surgery and its timing is a joint responsibility of
he patients’ cardiologist and cardiac surgeon.
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February 19, 2008:760–70 Year in Valvular Heart Diseasese of MVrep results in better outcomes than MVR: a
eview of 1,194 patients. A systematic review of 24 studies
howed 470 patients had MVrep and 724 had MVR (30).
Vrep compared with MVR was associated with a lower
30-day mortality (2.3% vs. 14.4%, p  0.0001) and
30-day mortality (7.8% vs. 40.5%, p  0.0001) (Fig. 5).
he use of MVrep also was associated with significantly
ower reoperation rates, recurrent endocarditis, and cerebro-
ascular events.
Comment: This is an important and useful review. Per-
ormance of MVrep requires: 1) the necessary surgical skill
nd experience, and 2) early surgery before extensive valve
estruction and extension of the infection beyond the valve
eaflets occur.
ime to early-onset PVE is up to 1 year. A total of 172
atients with PVE who were nondrug users were identified
rom 640 patients with IE. There were no statistically
ignificant differences in microbiological profile in those 2
onths and 2 to 12 months after PHV replacement (31).
ethicillin-resistant coagulase-negative staphylococci was
he most common pathogen.
Data from the International Collaboration on Endocarditis-
rospective Cohort Study in 2000 to 2005 showed PVE
ccurred in 556 (20.1%) of 2,670 patients with IE (32). The
ost common organisms were s. aureus (23%) and
oagulase-negative staphylococci (16.9%). Seventy-one per-
ent of health care-associated organisms occurred within the
rst year of valve implantation.
Comment: Calderwell et al. (33) showed in 1985 that the
ime of onset of early PVE was up to 1 year.
merican Heart Association Guidelines
n the Prevention of Infective Endocarditis (34)
omment: Very controversial.
atheter-Based Valvular Intervention
ransapical transcatheter AV implantation. Transapical
V was implanted in 7 patients, age 77  9 years, in whom
urgical risk for AVR “was deemed excessive because of
omorbidities” (35). Echocardiographic median AVA in-
Figure 5 Mitral Valve Repair and Replacement in Endocarditis:
From Feringa et al. (30).reased from 0.7  0.1 cm2 to 1.8  0.8 cm2 (interquartileanges). There were no intraprocedural deaths. At follow-up
f 87  56 days, 6 of 7 patients were alive and well.
Comment: This procedure was previously reported by
rofessor Mohr’s group in Leipzig (36). At the European
ociety of Cardiology Congress in September 2007, Mohr
pdated the data (37). The first patients were done in 2004;
essons were learned, and changes were made. The program
as restarted in 2006. As of September 2007, 122 valves
ere implanted, 30-day mortality was 6.5%; by the Society
f Thoracic Surgeons database criteria, the predicted mor-
ality would have been 20%. A total of 4.7% needed
mmediate conversion to open heart surgery. At 1 year, an
dditional 13.8% had died for an actuarial survival of 74.4
%. Reoperation rate was 1.6%.
stematic Review of Literature
Figure 6 Representation of Valved Stent Repositioning
(A) The valved stent has been voluntarily misplaced too proximally inside the
failed bioprosthesis. (B) Recompression of the valved stent. (C) The valved
stent has been ultimately placed in an adequate position. (D) Right lateral
view of the heart (right atrium and anterior part of right ventricle has been
resected showing “excellent” positioning of the valved stented inside the failed
bioprosthesis. From Zegdi et al. (38).A Sy
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Year in Valvular Heart Disease February 19, 2008:760–70ndovascular treatment of deteriorated bioprosthesis;
alve in a valve (VinV) procedure. Five sheep underwent,
n beating heart, tricuspid VR with a stented bioprosthesis.
rolapse of 1 leaflet was induced by tearing a leaflet, which
roduced severe TR. After surgical exposure of the infrare-
al inferior vena cava, the VinV procedure of repositioning
f valved stent (VS) was successful in all 5 sheep (Fig. 6)
38). The use of transthoracic echocardiography showed
nrestricted movements of the VS leaflets. There was no
R or periprosthetic regurgitation. Mean transvalvular gra-
ient was 7 mm Hg (range 6 to 8 mm Hg). The explanted
earts showed VS in good position, anchorage of the VS
nside the bioprosthesis was firm and the leaflets were
perfectly mobile” without macroscopic injury.
Comment: This study is another exciting development in
atheter-based valve implantation. At the European Society
f Cardiology Congress in September 2007, Mohr reported
n the first human and successful VinV procedure for
tructural valve deterioration of aortic bioprosthesis (37).
ercutaneous mitral annuloplasty: relationship of coro-
ary sinus (CS) to mitral valve annulus (MVann). In 61
xcised cadaveric human hearts, the maximum distance
etween CS to MVann was 19 mm (mean 9.7  3.2 mm)
39). The CS lies behind the left atrial wall not behind the
Vann; the implantation of a percutaneous mitral annulo-
lasty device into the coronary sinus could theoretically
esult in compression of the first diagonal artery and/or
Figure 7 Images From 64-Slice
Multislice Computed Tomography
Long-axis 2-chamber (A) and 4-chamber (B) were used to assess the course of
the coronary sinus (white arrow) in relation to the mitral valve annulus (MVann)
and the diameter of the MVann (black arrow). At the reconstructed level of the
MVann (C), the coronary sinus location and the MVann perimeter were deter-
mined. (D) Volume-rendered 3-dimensional reconstruction demonstrated the
course of the coronary sinus and its relation to the MVann and the left circum-
flex coronary artery. From Tops et al. (40).tamus branch in 16.4% of cases, of the circumflex artery in
3.9% cases, and of the AV nodal artery in 37.7% of cases.
In 105 patients, 64-slice MSCT was used to assess the
elationship of CS, MVann, and circumflex artery. The CS
as located along the left atrial wall, rather than along the
Vann, in the majority of patients ranging from 90% at the
evel of MVann to 14% at the level of the CS (Fig. 7) (40).
he minimal distance was 5.1  2.9 mm; in patients with
evere MR, the distance between CS and MVann was 7.3 
.9 mm, and in those without severe MR it was 4.8  2.5
p 0.05). In 68% of patients, the circumflex artery courses
etween the CS and MVann.
Long-term” outcomes after percutaneous mitral valvu-
oplasty (PMV). NEED FOR SURGERY. In 380 patients,
ommissural MR that originated at the site of successful
ommissurotomy occurred in 27 of 47 (57%). Noncom-
issural MR occurred in 20 of 47 (43%), of which 12 had
ubvalvular damage (ruptured chordae, fail leaflet) and 8
ad leaflet laceration. The 8-year event-free survival was
ower in those with severe MR versus without MR (47 
% vs. 83  3%, p  0.001) (41). Patients with
ommissural MR had a lower rate of MVR versus
oncommissural MR (15% vs. 70%, p  0.001). Multi-
ariate analyses showed significant predictors for MVR
ere atrial fibrillation (Afib), mean MVG after PMV,
nd noncommissural MR.
Fifty of 243 (21%) patients undergoing PMV needed
VR at a median interval of 6 months (range 0 to 130),
8% of whom had it within 15 days and 82% had it later.
urgery free survival at 5 years was 80% (42).
HYTHM CONTROL IS BETTER THAN RATE CONTROL: A
ANDOMIZED TRIAL. A total of 183 Chinese patients,
verage age 37 years with Afib of 12 months’ duration
ith a mean duration of 5.5 months were evaluated. A
ost-PMV LA size 45 mm, average size 40 mm, mean
eft atrial pressure 11 mm Hg, and MVA 1.8 cm2 were
andomized to rhythm control versus rate control (43). At 1
ear, the incidence of sinus rhythm in the 2 groups was 96%
nd 2%, respectively. Improvement in the primary end point
Afib-related symptoms) was greater in the rhythm group
approximately 80% vs. 30% to 40%, p  0.001 from Fig.
), who also had a better walking distance in the 6-min walk
est, quality of life, and LA size normalization. In this group
f patients, sinus rhythm was restored easily and was safe to
chieve and maintain.
Comment: It should be noted that this finding relates to
hose undergoing PMV for MS. The hemodynamics and
trial size were very favorable for conversion to and main-
aining sinus rhythm. It should not be extrapolated to
atients without valve disease or to other patients with valve
isease without proof from outcome data.
rosthetic Heart Valves
andomized trials. CARBOMEDICS VERSUS ST. JUDE. Up
o 10 years, there were no significant differences between the
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February 19, 2008:760–70 Year in Valvular Heart Diseasetypes of PHV with regard to survival (Fig. 8) and freedom
rom complications (44).
TENTLESS PHV: CRYOLIFE O’BRIEN VERSUS TORONTO. A
otal of 78 patients received valve sizes 21 to 29 mm. At 1
ear, AVA of Cryolife O’Brien was larger than the Toronto,
.81  0.50 versus 1.30  0.42 cm2, p  0.0001 (45).
Figure 8 Actuarial Survival Curves
Overall patient survival (A), freedom from valve-related death (B) after aortic valve
and mitral valve replacement (D). CI  confidence interval; CM  carbomedics; S
ineteen Variables That Independently Influencedperative Mortality (All p < 0.01): Society ofhor c c Surgeon Databas ; 409,904 Valvr cedures
Table 1
Nineteen Variables That Independently Influenced
Operative Mortality (All p < 0.01): Society of
Thoracic Surgeons Database; 409,904 Valve
Procedures
Odds Ratio*
Aortic root reconstruction 2.78
Tricuspid valve surgery 2.26
Nonelective (acute) presentation 2.11
Multiple valve procedures 2.06
Advanced age 1.88
Reoperation 1.61
Endocarditis 1.59
Coronary artery disease 1.58
Valve replacement versus valve repair 1.52
Isolated mitral 1.47
Female gender 1.37
Earlier year of operation 1.34
Reduced ejection fraction 1.34
Pulmonic 1.29
Any single other comorbidity 1.19
enal failure or multiple co-morbidities could be “very significant.” *Aortic operations were the
eference operation.
Data from Rankin et al. (49). eComment: It should be noted that small numbers of
atients in valves of several different sizes were included.
ore data are needed.
ost-effectiveness and economic value of AVR. With
he use of standard econometric techniques in 4,617 pa-
ients operated on from 1961 to 2003 and followed as of
005, the cost-effectiveness was $13,528 per quality-
djusted life year gained, $19,826 for octogenarians and
27,182 for nonagenarians (46).
The value of life-years proposed by economists was
pplied to determine the economic value of additional life
y AVR. The gross value was $14.6 billion, and expected
ain without surgery was estimated at $3.0 billion. The
et life-years gained were worth $11.6 billion and $451
ement (C)
t. Jude Medical. From Bryan et al. (44).
ortic Root Reconstructions (n  11,545)
Table 2 Aortic Root Reconstructions (n  11,545)
Incidence n (%)
Ascending aortic aneurysms 6,044 (52)
Aortic dissection 435 (4)
No aortic root pathology 5,066 (44)
Aortic stenosis 42.3%
Aortic stenosis or regurgitation 50.7%
Operative mortality for AVR with aortic root procedures for
Aortic aneurysm 10.5%
Aortic dissection 23.7%
No aortic root pathology 9.5%*
Isolated aortic valve replacement (AVR) without aortic root procedures was associated with an
perative mortality rate of 5.7%.replac
JM  SData from the Society for Thoracic Surgeons Database: 409,904 valve procedures [from Rankin
t al (49)].
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Year in Valvular Heart Disease February 19, 2008:760–70illion was cost of surgery, thus, the net value gained by
VR was $11.2 billion (47). The mean net value de-
reases according to age at surgery, $600,000 for octoge-
arians and $200,000 for nonogenarians.
Comment: Calculating the value of cardiothoracic proce-
ures to the economy of U.S. is an important and a new
irection of study (48).
perative (hospital) mortality. SOCIETY OF THORACIC
URGEONS DATABASE OF 409,904 VALVE PROCEDURES, 1994
O 2003. Aortic root reconstruction had the highest odds
atio (Table 1) (49). For a single AV procedure (n 
16,245) the unadjusted mortality was 5.7% and for AVR
aving aortic reconstruction when there was no aortic root
athology was 9.5% (Table 2). One of the main conclusions
f the authors was that “Because aortic root reconstruction
oubles mortality compared with simple aortic valve proce-
ures, root replacement should be reserved for specific root
athology.”
Comment: This study is an important one. Procedures
hat require root reconstruction without root pathology
nclude use of stentless valves, homografts and pulmonary
utografts (Ross principle).
EW YORK STATE CARDIAC SURGERY DATA. Data from
001 and 2003 showed hospital mortality for isolated valve
rocedures in 10,702 patients was 4.1%, for valve plus
oronary artery bypass graft CABG in 8,823 patients was
.9%. Risk scores were assigned and predicted mortality
elated to those scores was presented (50). For isolated valve
rocedures, the risk of hospital mortality ranged from 1%
o90% for risk scores of3 to34 and valve plus CABG
isks ranged from 1.18% to 90% for risk scores of 0 to
24.
Comment: One has to be cautious about use of these data
o determine risks at other centers because: 1) the findings
rom 2001 and 2003 were different from those in 1998 to
000 and may be very different in 2004 to 2006; and 2) data
rom New York may not be applicable to all of the U.S.
opulation.
Figure 9 Predicted Mortality After AVR in Octogenarians
in Relation to Preoperative LVEF
From Langanay et al. (51). AVR  aortic valve
replacement; LVEF  left ventricular ejection fraction.wortic valve replacement in octogenarians. From 2000 to
nd of 2004, 442 consecutive patients aged 80 years (82.7
2.3 years; 14% 85 years) had AVR. These octogenar-
ans represented 16% of 2,760 patients who had AVR.
ospital mortality was 7.5% (51). On multivariate analysis,
he predictors of mortality were LVEF (p  0.003),
mergency surgery (p  0.017), and “redo” surgery (p 
.002). Without these risk factors, the risks were low (Fig.
). The actual mortality matched those predicted from
uroScore.
Comment: This is a valuable study.
ngineering living heart valves. “Prenatal fetal progeni-
ors obtained from routine chorionic villus sampling were
uccessfully used as an exclusive, new cell source for the
ngineering living heart valve leaflets” (52).
Comment: These cell sources should be an improvement
o the development of tissue-engineered valves.
alve prosthesis-patient mismatch (VP-PM). IMPACT
F VP-PM WITH MVR. In 929 consecutive patients, VP-PM
as classified on the basis of the projected MVA indexed for
ody surface area: 1.2 cm2/m2 as “not clinically signifi-
ant” was present in 22%, 0.9 and 1.2 cm2/m2 as
oderate in 69%, and 0.9 cm2/m2 as severe VP-PM
resent in 9% (53). Patients with severe VP-PM had lower
-year and 12-year survival (74 5% and 63 7%) than for
atients with moderate VP-PM (84  1% and 76  2%, p
0.027) or clinically not significant (90  2% and 82 
%, p  0.002) (Fig. 10). On multivariate analysis, severe
P-PM was associated with a greater mortality (hazard
atio 3.2, 95% confidence interval 1.5 to 6.8, p  0.003).
Comment: This is the first detailed study of VP-PM after
VR that adds to many valuable contributions by Pibarot
nd Dumesnil.
In 884 patients mitral VP-PM, defined as MVA 1.25
m2/m2, was present in 32%. Mitral VP-PM was associated
Figure 10 Overall Survival After Mitral Valve Replacement in
Patients With Valve Prosthesis-Patient Mismatch
From Magne et al. (53).ith elevated mean MVG, recurrent HF (p  0.05). When
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February 19, 2008:760–70 Year in Valvular Heart Diseaseompared with “without” VP-PM survival was worse at 5
ears (78% vs. 86%) and at 10 years (65% vs. 75%) (54).
ORTIC VP-PM HAS WORSE OUTCOMES IN PATIENTS WITH
OW-GRADIENT AS (LG-AS). The authors found that LG-
S, defined as AVA 1.2 cm2, mean aortic valve gradient
40 mm Hg, and LVEF 0.50, was present in 79 of 664
12%) patients (55). In LG-AS patients, VP-PM (defined
s AVA index of 0.85 cm2/m2) was independently asso-
iated with increased rates of HF (hazard ratio 3.6  2.2, p
0.039), impaired LV mass regression (p  0.037), and a
trend” toward increased late mortality (hazard ratio 3.0 
.9, p  0.084).
EST METHOD TO PREDICT VP-PM PRIOR TO AVR? The
HV area was obtained in 383 patients with echocardiog-
aphy at 6 months after AVR. The preoperative prediction
f VP-PM obtained in these patients was tested by 4
ethods: 1) PHV areas obtained in “normal” PHV from
chocardiography at 6 months after valve replacement in
heir own laboratory; 2) indexed geometric orifice area
alculated from the internal diameter provided by the
anufacturer; 3) PHV areas estimated from charts provided
y PHV manufacturers (which are based either on in vitro
r on echo data); and 4) PHV areas estimated from
eference echo data published in the literature to predict
P-PM (56). The sensitivity to predict VP-PM by method
(previous medical records based on echo data at 6 months
fter AVR), method 3, and method 4 were 53%, 80%, and
1%, respectively, and the specificity of these 3 methods was
3%, 53%, and 67%, respectively. The sensitivity of method
and of charts based on in vitro data (parts of method 3) to
redict VP-PM was 0% to 17%. The incidence of VP-PM
ould be reduced from 8.7% to 0.8% with the use of method
(p  0.003). Method 1 was the best.
iscellaneous
rug-induced VHD. Ergot-derived dopamine agonists,
ergolide and cabergoline, which were used in the treatment
f Parkinson’s disease and the restless leg syndrome, caused
ardiac-valve regurgitation (57,58).
Comment: This was first described in 2002 (59,60).
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 2025 Zonal Avenue,
NH 7131, Los Angeles, California 90033. E-mail: rahimtoo@
sc.edu.
EFERENCES
1. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006
guidelines for the management of patients with valvular heart disease:
a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee
to Revise the 1998 Guidelines for the Management of Patients With
Valvular Heart Disease). J Am Coll Cardiol 2006;48:e1–148.2. Vahainan A, Baumgartner H, Bax J, et al. Guidelines on the
management of valvular heart disease. Eur Heart J 2007;28:230–68.3. Aikawa E, Nahrendorf M, Sosnovik D, et al. Multimodality molecular
imaging identifies proteolytic and osteogenic activities in early aortic
valve disease. Circulation 2007;115:377–86.
4. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific
aortic valve stenosis in old hypercholesterolemic mice. Circulation
2006;114:2065–9.
5. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M,
Whooley MA. Association of Fetuin-A with mitral annular calcifica-
tion and aortic stenosis among persons with coronary heart disease.
Data from the Heart and Soul study. Circulation 2007;115:2533–9.
6. Burke AP, Kolodgie FD, Virmani R. Fetuin-A, valve calcification and
diabetes. What do we understand? Circulation 2007;115:2464–7.
7. Clark-Greuel JN, Connolly JM, Sorichillo E, et al. Transforming
growth factor- 1 mechanisms in aortic valve calcification: increased
alkaline phosphatase and related events. Ann Thorac Surg 2007;83:
946–53.
8. Ortlepp JR, Pillich M, Schmitz F, et al. Lower calcium levels are
associated with greater calcium hydroxyapatite deposition in native
aortic valves of male patients with severe calcific aortic stenosis. J Heart
Valve Dis 2006;15:502–8.
9. Ortlepp JR, Pillich M, Mevissen V, et al. APOE alleles are not
associated with calcific aortic stenosis. Heart 2006;92:1463–6.
0. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting
aortic valve endothelium to slow progression of aortic stenosis. J Am
Coll Cardiol 2007; 49:554–61.
1. Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes
after aortic valve surgery for severe chronic aortic regurgitation with
severe LV dysfunction. J Am Coll Cardiol 2007;49:1465–71.
2. Clark DG, McAnulty JH, Rahimtoola SH. Valve replacement in
aortic insufficiency with left ventricular dysfunction. Circulation 1980;
61:411–21.
3. Aicher D, Urbich C, Zeiher A, Dimmeler S, Schäfers HJ. Endothelial
nitric oxide synthase in bicuspid aortic valve disease. Ann Thorac Surg
2007;83:1290–4.
4. Grotenhuis HB, Ottenkamp J, Westenberg JJM, Bax JJ, Kroft LJM,
de Ross A. Reduced aortic elasticity and dilatation are associated with
aortic regurgitation and left ventricular hypertrophy in nonstenotic
bicuspid aortic valve patients. J Am Coll Cardiol 2007;49:1660–5.
5. Messika-Zeitoun D, Serfaty JM, Laissy JP, et al. Assessment of mitral
valve area in patients with mitral stenosis by multislice computed
tomography. J Am Coll Cardiol 2006;48:411–3.
6. Kyndt F, Gueffet JP, Probst V, et al. Mutations in the gene encoding
filamin A as a cause for familial cardiac valvular dystrophy. Circulation
2007;115:40–9.
7. Chang BC, Youn YN, Ha JW, Lim SH, Hong YS, Chung N.
Long-term clinical results of mitral valvuloplasty using flexible and
rigid rings: a prospective and randomized study. J Thorac Cardiovasc
Surg 2007;133:995–1003.
8. Mirabel M, Iung B, Baron G, et al. What are the characteristics of
patients with severe symptomatic, mitral regurgitation who are denied
surgery? Eur Heart J 2007;28:1358–65.
9. Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson EB.
Influence of hospital procedural volume on care process and mortality
for patients undergoing elective surgery for mitral regurgitation.
Circulation 2007;115:881–7.
0. Detaint D, Sundt TM, Nkomo VT, et al. Surgical correction of mitral
regurgitation in the elderly. Outcomes and recent improvements.
Circulation 2006;114:265–72.
1. Ton-Nu T-T, Levine RA, Handschumacher MD, et al. Geometric
determinants of functional tricuspid regurgitation. Insights from
3-dimensional echocardiography. Circulation 2006;114:143–9.
2. Tang GHL, David TE, Singh SK, Maganti MD, Armstrong S,
Borger MA. Tricuspid valve repair with an annuloplasty ring results in
improved long-term outcomes. Circulation 2006;114 Suppl I:577–81.
3. Revilla A, Lopez J, Vilacosta I, et al. Clinical and prognostic profile of
patients with infective endocarditis who need urgent surgery. Eur
Heart J 2007;28:65–71.
4. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Magati
MD. Surgical treatment of active infective endocarditis: a continued
challenge. J Thorac Cardiovasc Surg 2007;133:144–9.
5. Hill FE, Herijgers P, Claus P, et al Infective endocarditis: changing
epidemiology and predictors of 6-month mortality: a prospective
cohort study. Eur Heart J 2007;28:196–203.
22
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
770 Rahimtoola JACC Vol. 51, No. 7, 2008
Year in Valvular Heart Disease February 19, 2008:760–706. Remadi JP, Habib G, Nadji G, et al Predictors of death and impact of
surgery in Staphylococcus aureus infective endocarditis. Ann Thorac
Surg 2007;83:1295–302.
7. Slater MS, Komanapalli CB, Tripathy U, Ravichandran PS, Unger-
leider RM. Treatment of endocarditis: a decade of experience. Ann
Thorac Surg 2007;83:2074–80.
8. Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD.
Epidemiology and clinical outcomes of infective endocarditis in
hemodialysis patients. Ann Thorac Surg 2007;83:2081–6.
9. Tleyjeh IM, Ghomrawi HMK, Steckelberg JM, et al. The impact of
valve surgery on 6-month mortality in left-sided infective endocarditis.
Circulation 2007; 115:1721–8.
0. Feringa HHH, Shaw LJ, Poldermans D, et al. Mitral valve repair and
replacement in endocarditis: a systematic review of literature. Ann
Thorac Surg 2007;83:564–70.
1. Lopez J, Revilla A, Villacosta I, et al. Definition, clinical profile,
microbiological spectrum and prognostic factors of early-onset pros-
thetic valve endocarditis. Eur Heart J 2007;28:760–5.
2. Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile
and outcome of prosthetic valve endocarditis. JAMA 2007;297:1354–
61.
3. Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW,
Buckley MJ. Risk factors for the development of prosthetic valve
endocarditis. Circulation 1985;72:31–37.
4. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective
endocarditis: guidelines from the American Heart Association: a
guideline from the American Heart Association Rheumatic Fever,
Endocarditis, and Kawasaki Disease Committee, Council on Cardio-
vascular Disease in the Young, and the Council on Clinical Cardiol-
ogy, Council on Cardiovascular Surgery and Anesthesia, and the
Quality of Care and Outcomes Research Interdisciplinary Working
Group (erratum appears in Circulation 2007;116:e376–7). Circulation
2007;116:1736–54.
5. Lichtenstein SV, Cheung A, Thompson CR, et al Transapical
transcatheter aortic valve implantation in humans: initial clinical
experience. Circulation 2006;114:591–6.
6. Ye J, Cheung A, Lichtenstein SV, et al. Transapical aortic valve
implantation in humans. J Thorac Cardiovasc Surg 2006;131:1194–6.
7. Mohr FW. Transapical valve implantation in aortic stenosis: an
update. Symposium. European Society of Cardiology Congress, Sep-
tember 4, 2007, Vienna, Austria.
8. Zegdi R, Khabbaz Z, Borenstein N, Fabiani JN. A repositionable
valved stent for endovascular treatment of deteriorated bioprosthesis.
J Am Coll Cardiol 2006;48:1365–8.
9. Maselli D, Guarracino F, Chiaramonti F, Mangia F, Borelli G,
Minzioni G. Percutaneous mitral annuloplasty: an anatomic study of
human coronary sinus and its relation with mitral valve annulus and
coronary arteries. Circulation 2006; 114:377–80.
0. Tops LF, VandeVeire NR, Schuijf JD, et al. Noninvasive evaluation of
coronary sinus anatomy and its relation to the mitral valve annulus.
Implications for percutaneous mitral annuloplasty. Circulation 2007;
115:1426–32.
1. Kim MJ, Song JK, Song JM, et al Long-term outcomes of significant
mitral regurgitation after percutaneous mitral valvuloplasty. Circula-
tion 2006;114:2815–22.
2. Zimmett AD, Almeida AA, Harper RVV, et al. Predictors of surgery
after percutaneous mitral valvuloplasty. Ann Thorac Surg 2006;82:
828–33.3. Hu CL, Jiang H, Tang QZ, et al Comparison of rate control and
rhythm control in patients with atrial fibrillation after percutaneous
mitral balloon valvotomy: a randomized controlled study. Heart
2006;92:1096–101.
4. Bryan AJ, Rogers CA, Bayliss K, Wild J, Angelini GD. Prospective
randomized comparison of CarboMedics and St. Jude Medical bileaf-
let mechanical heart valve prosthesis: Ten-year follow-up. J Thorac
Cardiovasc Surg 2007;133:614–22.
5. Chambers JB, Rimington HM, Rajani R, Hodson F, Shabbo F. A
randomized comparison of Cryolife O’Brien and Toronto stentless
replacement aortic valves. J Thorac Cardiovasc Surg 2007;133:1045–
50.
6. Wu Y-X, Jin R, Gao G, Grunkemeier GL, Starr A. Cost effectiveness
of aortic valve replacement in the elderly: an introductory study.
J Thorac Cardiovasc Surg 2007;133:608–13.
7. Wu Y-X, Grunkemeier GL, Starr A. The value of aortic valve
replacement in elderly patients: an economic analysis. J Thorac
Cardiovasc Surg 2007;133:603–7.
8. Starr A, Grunkemeier GL. The cost and value of cardiothoracic
procedures. J Thorac Cardiovasc Surg 2007;133:601–2.
9. Rankin JS, Hammill BG, Ferguson TB Jr., et al. Determinants of
operative mortality in valvular heart surgery. J Thorac Cardiovasc Surg
2006;133:547–57.
0. Hannan EL, Wu C, Bennett EV, et al. Risk index for predicting
in-hospital mortality for cardiac valve surgery. Ann Thorac Surg
2007;83:921–30.
1. Langanay T, Verhoye JP, Ocampo G, et al. Current hospital mortality
of aortic valve replacement in octogenarians. J Heart Valv Dis
2006;15:630–63.
2. Schmidt D, Mol A, Breymann C, et al. Living autologous heart valves
engineered from human prenatally harvested progenitors. Circulation
2006;114 Suppl 1: 125–31.
3. Magne J, Mathieu P, Dumesnil JC, et al. Impact of prosthesis-patient
mismatch on survival after mitral valve replacement. Circulation
2007;115:1417–25.
4. Lam B-K, Chan V, Hendry P, et al. The impact of patient-prosthesis
mismatch on late outcomes after mitral valve replacement. J Thorac
Cardiovasc Surg 2007; 133:1464–73.
5. Kulik A, Burwash IG, Kapila V, Mesana TG, Ruel M. Long-term
outcomes after aortic valve replacement for low-gradient aortic steno-
sis. Impact of prosthesis-patient mismatch. Circulation 2006;114
Suppl 1:553–8.
6. Bleiziffer S, Eichinger WB, Hettioh I, et al. Prediction of valve-
prosthesis-patient mismatch prior to aortic valve replacement: which is
the best method? Heart 2007;93:615–20.
7. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopa-
mine agonists and the risk of cardiac valve regurgitation. N Engl J Med
2007;356:29–38.
8. Zainettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.
Valvular heart disease and the use of dopamine agonists for Parkinson’s
Disease. N Engl J Med 2007; 356:39–46.
9. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly
HM, Espinosa RE. Valvular heart disease in patients taking pergolide.
Mayo Clin Proc 2007; 77:1280–6.
0. Rahimtoola SH. Drug-related valvular heart disease; Here we go
again: Will we do better this time? Mayo Clin Proc 2002;77:1275–7.
